Ibtrozi (taletrectinib) — Medica
non-small cell lung cancer (NSCLC)
Initial criteria
- Patient is age ≥ 18 years
- Patient has locally advanced or metastatic disease
- Patient has ROS1-positive non-small cell lung cancer
- ROS1 mutation was detected by an approved test
Approval duration
1 year